Tofogliflozin is a SGLT-2 inhibitor type 2 diabetes drug developed by Chinese and foreign pharmaceutical companies. It is a sodium glucose co transporter 2 inhibitor. Its advantage lies in its high selectivity. The drug plays a hypoglycemic effect by inhibiting the reabsorption of glucose by the kidneys and inducing excessive glucose excretion in the blood. The compound has a unique mechanism independent of insulin. In addition to improving fasting blood glucose and postprandial blood glucose, it also has low-risk hypoglycemia inducing events and has a significant effect on weight loss.